Oric Pharmaceuticals Inc. (ORIC)
NASDAQ: ORICHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ORIC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $764.94M
- EPS (TTM)
- -$1.44
- Dividend yield
- None
- 52-week range
- 7.23 – 14.68
- Day range
- 7.28 – 8.00
- Volume / Avg
- 1.46M / 1.59M
- Beta
- —
- Shares outstanding
- 103.93M
52-week range
ORIC stock today
Oric Pharmaceuticals (ORIC) closed at $7.36 on Nov 20, down 4.42% (-$0.34), versus the S&P 500's 3.70% decline. Shares are 49.9% below their 52-week high of $14.68, set on Aug 19, 2026 and 1.8% above the 52-week low of $7.23, near the bottom of the past year's range. ORIC is down 10.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.7%.
Oric Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Oric Pharmaceuticals
Company profileORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jacob M. Chacko M.B.A., M.D.
- Headquarters
- South San Francisco, CA
- Employees
- 111
- IPO year
- 2020
- Website
- oricpharma.com
Financial highlights
Full financialsOric Pharmaceuticals reported a net loss of $129.5 million, compared with a loss of $127.8 million a year earlier. Diluted earnings per share came in at -$1.47.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-129.47M | $-127.85M | $-100.70M | $-89.12M | $-78.72M |
| EPS (diluted) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$21.71+194.97%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.44 vs $-0.41
- Surprise
- -7.32%
ORIC news
All ORIC news- ORIC Pharmaceuticals Reports Third Quarter 2026 Financial Results and Program UpdatesNasdaq
- ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program UpdatesGlobeNewswire
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- ORIC Pharmaceuticals, Inc. Announces Phase 1b Enozertinib Data and Plans for Phase 3 Redwood-1 Trial in 1H 2027NasdaqORIC, WSO.B
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialGlobeNewswire
- ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026GlobeNewswire
Oric Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs ORIC |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs ORIC |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs ORIC |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs ORIC |
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs ORIC |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs ORIC |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs ORIC |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs ORIC |
Indexes, lists and sector
Oric Pharmaceuticals stock FAQ
What is Oric Pharmaceuticals's stock price today?
ORIC last traded at $7.36 as of Nov 20, 4:00 PM EST, down 4.42% on the day. Prices are delayed at least 15 minutes.
Who is Oric Pharmaceuticals's CEO?
Dr. Jacob M. Chacko M.B.A., M.D. is the chief executive officer of Oric Pharmaceuticals Inc., which has about 111 employees.
What is the ORIC 52-week high?
The 52-week high for ORIC is $14.68 and the 52-week low is $7.23. The stock is currently 49.9% below its high.